Current Edition

approval

CStone’s PD-1 inhibitor CS1003 gets clinical trial approval in China

CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003 in Chinese patients with advanced …

Continue Reading →